semaglutide and hypertension CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Semaglutide and Cardiovascular Protection: Beyond

Aljumaah MR, Bhatia U, Roach J, Gunstad J, Peril MAA

The findings come at a moment when scientists are exploring the use of GLP-1 drugs to treat other conditions beyond type 2 diabetes and obesity, such as sleep apnea and addiction

Abstract To exclude an excess risk of cardiovascular (CV) events, CV outcomes trials (CVOTs) have assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), in patients with type 2 diabetes and established CV disease or CV risk factors

Human clinical trials and observational clinic data both show this signal

Archived from the original on 19 June 2019